Cancer immunotherapy is a very successful treatment principle mainly driven by checkpoint inhibitors. These, and emerging immunotherapies, only work on a limited number of cancer types, because they depend on a high tumor mutation load. Most cancers have dramatically fewer mutations than the melanomas, non-small cell lung cancers and bladder cancer in which checkpoint inhibitors reach their high efficacy. An opportunity exists for the introduction of an effective immunotherapy that works on cancers with lower tumour mutation load, especially if such a product can synergize with checkpoint inhibitors.
Inprother is developing a cancer vaccine
Inprother is developing a cancer vaccine using human Endogenous Retroviruses (ERVs) as antigens. ERVs are highly associated with several forms of cancer (Breast, Prostate, HNSCC, Renal, Ovarian, Melanoma, colorectal, hematological, liver and sarcomas), and are required for tumor development in mice. When encoding ERVs in a viral vector using InProThers vaccine platform, we obtained impressive immune responses and anticancer efficacy. We have generated strong preclinical proof of concept, proving ability to cure established cancers and subsequently induce resistance to different cancer types. The vaccine show strong synergy with checkpoint inhibitors, where the combination cure 100% of the animals from small colorectal cancers.
The preclinical data and its usefulness to support clinical translation have been discussed with key opinion leaders who unanimously endorse the approach.
The target product is a vaccine administered to patients in 2 doses. Main competitive advantages vs competition are:
- Efficacy – Effective curative and prophylactic cancer vaccines.
- Platform -Each product can target multiple cancers.
- IPR – Requirement of patented innovations to elicit protective responses.
- Clinically validated gold-standard delivery technology – Using Adenovirus and Poxvirus.
- COGS – Standard medicine leading to low manufacturing cost.
Read about our scientific articles here.